Becton Dickinson (BDX) Stock
Key stats
- Market cap
- $58.43B
- Price / Earnings ratio
- 61.5x
- EPS (TTM)
- $3.32
- Volume
- Loading
- 52-week high
- $216.74
- 52-week low
- $140.11
- Dividend yield
- 1.96%
- Dividend amount (latest)
- $1.05
- EPS vs analyst estimate
- +1.3%Q4 FY25 · $3.96 vs $3.91
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with BDX
Recent news

BDX Gears Up to Report Q4 Results: How to Play the Stock?
BDX Gears Up to Report Q4 Results: How to Play the Stock?
BDX

Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
BDX

BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment
BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment
BDX

Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
BDX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 72.89
- MACD 12/26/9
- 7.17
- EMA 9 of MACD
- 5.82
- MACD histogram
- 1.35
- SMA 50
- $189.76
- Price above SMA 50
- EMA 50
- $192.23
- Price above EMA 50
- SMA 200
- $169.88
- Price above SMA 200
- EMA 200
- $179.51
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $4.73 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

BDX Gears Up to Report Q4 Results: How to Play the Stock?
BDX Gears Up to Report Q4 Results: How to Play the Stock?
BDX

Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
BDX

BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment
BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment
BDX

Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
BDX

BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
BDX

BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
BDX

3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades
3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades
BDX

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
BDX

Becton Dickinson to invest $19 billion in US
Becton Dickinson to invest $19 billion in US
BDX

Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing
Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing
BDX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Becton Dickinson
Becton Dickinson is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving the drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; advancing research and applications; and supporting the management of diabetes.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas E. Polen Jr. | President, CEO & Chairman | 1973 |
| Mr. Vitor Roque | Executive VP & CFO | 1983 |
| Mr. Michael C. Feld | Executive VP & Chief Revenue Officer | 1981 |
| Ms. Elizabeth McCombs | Executive VP & CTO | 1977 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior VP & Chief Scientific Officer | — |
| Mr. Arthur Hu | Executive VP and Chief Information & Digital Officer | — |
| Mr. Shawn C. Bevec | Senior Vice President of Investor Relations | — |
| Ms. Lanesha T. Minnix J.D. | Executive VP & General Counsel | 1975 |
| Carla Burigatto | Senior VP & Chief Communications Officer | — |
| Ms. Meera Gopalakrishnan | Senior VP & Global Chief Marketing Officer | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 72.89
- MACD 12/26/9
- 7.17
- EMA 9 of MACD
- 5.82
- MACD histogram
- 1.35
- SMA 50
- $189.76
- Price above SMA 50
- EMA 50
- $192.23
- Price above EMA 50
- SMA 200
- $169.88
- Price above SMA 200
- EMA 200
- $179.51
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $195.00
- Average
- $216.88
- High
- $242.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.7 | +4.1 | ||||||||||
| 2022 | +0.4 | +7.1 | -2.0 | -5.8 | +4.2 | -1.9 | -3.0 | +3.1 | -12.7 | +2.2 | +6.6 | +1.4 |
| 2023 | -1.5 | -7.7 | +6.6 | +7.0 | -8.9 | +6.4 | +6.4 | +0.3 | -7.2 | -1.9 | -6.9 | +2.3 |
| 2024 | -2.7 | -2.8 | +5.2 | -3.9 | -0.7 | -2.1 | +5.1 | +2.7 | -0.4 | -3.3 | -5.7 | +1.8 |
| 2025 | +9.3 | -8.9 | +0.3 | -8.4 | +1.8 | +1.7 | +0.3 | +9.4 | -0.5 | -6.4 | +9.4 | +1.2 |
| 2026 | +4.4 | -12.6 | -10.9 | -4.7 | -1.5 | +4.1 | +8.3 | +10.5 | -4.3 | +11.1 | +8.0 |



